Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)
July 13, 2022 06:30 AM EDTUpdated 12:11 PM
R&D

Cur­tain-rais­er da­ta keep an­a­lysts on edge ahead of Am­gen’s big Lumakras/PD-1 com­bo read­out

Amber Tong

Will a com­bi­na­tion reg­i­men bring Am­gen’s big KRAS drug to new heights?

That’s the ma­jor ques­tion Wall Street found it­self mulling in the wake of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times